Drug
Ifinatamab Deruxtecan
Ifinatamab Deruxtecan: highest development phase Phase 3, developed by Daiichi Sankyo, Merck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Daiichi Sankyo, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ifinatamab deruxtecan NCT06925737 | Phase 3 | Prostate Cancer |
| Ifinatamab Deruxtecan NCT07630974 | Phase 1/2 | Malignant Neoplasm |
| Ifinatamab deruxtecan (I-DXd) NCT04145622 | Phase 1/2 | Advanced Solid Tumor |
Latest
No recent events.
Follow Ifinatamab Deruxtecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.